natgillin/translations-raw huggingface dataset:
Varje tablett innehåller 16 mg, 24 mg, 60 mg eller 160 mg maropitant som maropitantcitratmonohydrat.
Each tablet contains 16 mg, 24 mg, 60 mg or 160 mg maropitant as maropitant citrate monohydrate.
Varje tablett innehåller 160 mg maropitant som maropitantcitratmonohydrat.
Each tablet contains 160 mg maropitant as maropitant citrate monohydrate.
Varje tablett innehåller 24 mg maropitant som maropitantcitratmonohydrat.
Each tablet contains 24 mg maropitant as maropitant citrate monohydrate.
Varje tablett innehåller 60 mg maropitant som maropitantcitratmonohydrat.
Each tablet contains 60 mg maropitant as maropitant citrate monohydrate.
Varje tablett innehåller:
Each tablet contains:
Varje tuggtablett innehåller antingen 1 mg eller 2,5 mg meloxikam, som motsvarar den dagliga underhållsdosen för en hund med 10 kg kroppsvikt respektive en hund med 25 kg kroppsvikt.
Each chewable tablet contains either 1 mg or 2.5 mg meloxicam, which corresponds to the daily maintenance dose for a 10 kg body weight dog, or a 25 kg body weight dog respectively.
Varje tuggtablett kan halveras för noggrann dosering enligt djurets individuella kroppsvikt.
Each chewable tablet can be halved for accurate dosing according to the individual body weight of the animal.
Varje tuggtablett kan halveras för noggrann dosering enligt djurets individuella kroppsvikt.
Each chewable tablet can be halved for accurate dosing according to the individual body weight of the dog.
Varningar och försiktighet
Special warnings and precautions for use
Varnost in učinkovitost palonosetrona i.v. pri enojnem odmerku 1 µg/kg in 3 µg/kg so primerjali v prvi klinični študiji s 150 bolniki v naslednjih starostnih skupinah: > 28 dni do 23 mesecev (7 bolnikov), 2 do 11 let (96 bolnikov) in 12 do 16 let (47 bolnikov) z elektivno operacijo.
>28 days to 23 months (7 patients), 2 to 11 years (96 patients), and 12 to 16 years of age (47 patients) undergoing elective surgery.
Varnost in učinkovitost palonosetrona i.v. pri enojnem odmerku 3 µg/kg in 10 µg/kg so raziskovali v prvi klinični študiji z 72 bolniki v naslednjih starostnih skupinah: >28 dni do 23 mesecev (12 bolnikov), 2 do 11 let (31 bolnikov) in 12 do 17 let (29 bolnikov), ki so prejemali zelo ali zmerno emetogeno kemoterapijo.
The safety and efficacy of palonosetron intravenously at single doses of 3 μg/kg and 10 μg/kg was investigated in the first clinical study in 72 patients in the following age groups, >28 days to 23 months (12 patients), 2 to 11 years (31 patients), and 12 to 17 years of age (29 patients), receiving highly or moderately emetogenic chemotherapy.
Varnost in učinkovitost ustekinumaba so ocenili pri 1.996 bolnikih v dveh randomiziranih, dvojno slepih in s placebom nadzorovanih študijah pri bolnikih z zmerno do hudo psoriazo s plaki, ki so bili kandidati za fototerapijo ali sistemsko terapijo.
The safety and efficacy of ustekinumab was assessed in 1,996 patients in two randomised, double-blind, placebo-controlled studies in patients with moderate to severe plaque psoriasis and who were candidates for phototherapy or systemic therapy.
Varnost in učinkovitost ustekinumaba so ocenjevali pri 927 bolnikih z aktivnim PsA (≥ 5 oteklih sklepov in ≥ 5 občutljivih sklepov) v dveh randomiziranih, dvojno slepih, s placebom nadzorovanih študijah, ki so prejemali tudi nesteroidna protivnetna (NSAID) ali protirevmatična (DMARD) zdravila.
The safety and efficacy of ustekinumab was assessed in 927 patients in two randomised, double-blind, placebo-controlled studies in patients with active PsA (≥ 5 swollen joints and ≥ 5 tender joints) despite non-steroidal anti-inflammatory (NSAID) or disease modifying antirheumatic (DMARD) therapy.
Varnost in učinkovitost ustekinumaba so ocenjevali v treh randomiziranih, dvojno slepih, s placebom nadzorovanih, multicentričnih študijah pri odraslih bolnikih z zmerno do močno aktivno Crohnovo boleznijo (indeks aktivnosti Crohnove bolezni [CDAI] ≥ 220 in ≤ 450).
The safety and efficacy of ustekinumab was assessed in three randomized, double-blind, placebo- controlled, multicenter studies in adult patients with moderately to severely active Crohn’s disease (Crohn’s Disease Activity Index [CDAI] score of ≥ 220 and ≤ 450).
Varnost in učinkovitost zdravila INOmax pri nedonošenčkih, rojenih po manj kot 34 tednih nosečnosti, še nista ugotovljeni.
The safety and efficacy of INOmax in premature infants less than 34 weeks of gestation has not yet been established.
Varnost in učinkovitost zdravila Pramipeksol Accord pri otrocih, mlajših od 18 let, še nista dokazani.
The safety and efficacy of Pramipexole Accord in children below 18 years has not been established.
Varnost in učinkovitost zdravila STELARA pri zdravljenju Crohnove bolezni pri otrocih, mlajših od 18 let, nista bili dokazani.
The safety and efficacy of STELARA for the treatment of Crohn’s disease in children less than 18 years have not yet been established.
Varnost in učinkovitost zdravila STELARA pri zdravljenju Crohnove bolezni pri otrocih, mlajših od 18 let, nista bili dokazani.
The safety and efficacy of STELARA in treatment of Crohn’s disease in children less than 18 years have not yet been established.
Varnost in učinkovitost zdravila STELARA v kombinaciji z imunosupresivi, vključno z biološkimi zdravili ali fototerapijo, v študijah psoriaze nista bili ovrednoteni.
In psoriasis studies, the safety and efficacy of STELARA in combination with immunosuppressants, including biologics, or phototherapy have not been evaluated.
Varnost in učinkovitost zdravila Teysuno pri otrocih in mladostnikih, starih pod 18 let, še nista bili dokazani.
The safety and efficacy of Teysuno in children and adolescents under 18 years old have not been established.
Varnost in učinkovitost zoledronske kisline pri otrocih od 1 do 17 let starosti nista ugotovljeni.
The safety and efficacy of zoledronic acid in children aged 1 year to 17 years have not been established.
Varnost je bila ocenjena pri bolnikih, ki so bili naključno izbrani za prejemanje pemetrekseda (N=800).
Safety was assessed for patients who were randomised to receive pemetrexed (N=800).
Varnost ustekinumaba so preučevali v študiji faze 3 pri 110 bolnikih, starih od 12 do 17 let, do največ 60 tednov.
The safety of ustekinumab has been studied in a phase 3 study of 110 patients from 12 to 17 years of age for up to 60 weeks.
Varnost zdravila med laktacijo ni dokazana.
The safety of the veterinary medicinal product has not been established during lactation.
Varnost zdravila za uporabo v veterinarski medicini v obdobju brejosti in laktacije ni bila ugotovljena (glejte razdelek 4.3).
The safety of the veterinary medicinal product has not been established during pregnancy and lactation (see section 4.3).
Varvara, Athens, Гърция
Varvara, Athens, Greece
Vaskulaarsed häired
Vascular disorders
Vastunäidustused
Contraindications
Vatten för injektion
Shelf life
Vatten för injektion
Water for injections
Vatten för injektion
Water for injections.
Vatten för injektionsvätskor
Water for injections
Vaxelis е ваксина, която помага да се предпази Вашето дете от дифтерия, тетанус, коклюш, хепатит B, полиомиелит и сериозни заболявания, причинявани от Haemophilus influenzae тип b.
Vaxelis is a vaccine, which helps to protect your child against diphtheria, tetanus, pertussis, hepatitis B, poliomyelitis and serious diseases caused by Haemophilus influenzae type b.
Vaxelis е ваксина, която съдържа активни вещества, извлечени от бактериите, причиняващи дифтерия, тетанус, коклюш и Haemophilus influenzae тип b, вируса на хепатит В и инактивирани полиовируси.
Vaxelis is a vaccine containing active substances derived from diphtheria, tetanus, pertussis and Haemophilus influenzae type-b bacteria, the hepatitis B virus, and inactivated polioviruses.
Vaxelis инжекционна суспензия в предварително напълнена спринцовка
Vaxelis suspension for injection in pre-filled syringe.
Vaxelis инжекция i.m.
Vaxelis injection IM
Vaxelis може да се приложи по едно и също време с други ваксини като пневмококови ваксини, ваксини срещу морбили-паротит-рубеола-варицела (MMRV), ротавирусни ваксини или менингококови С ваксини.
Vaxelis can be given at the same time as other vaccines such as pneumococcal vaccines, measles- mumps-rubella-varicella (MMRV) vaccines, rotavirus vaccines or meningococcal C vaccines.
Vaxelis не защитава Вашето дете от болести, причинени от други бактерии и вируси, които могат да предизвикат подобни симптоми.
Vaxelis does not protect your child against diseases caused by other bacteria and viruses that may cause similar symptoms.
Vaxelis не предпазва от заболявания, причинени от други типове Haemophilus influenzae освен тип b или от други микроорганизми, причиняващи инвазивно заболяване като менингит или сепсис, включително N. meningitidis.
Vaxelis does not protect against disease caused by Haemophilus influenzae other than type b or by other microorganisms that cause invasive disease such as meningitis or sepsis, including N. meningitidis.
Vaxelis няма да предпази от заболявания, причинени от други патогени различни от Corynebacterium diphtheriae, Clostridium tetani, Bordetella pertussis, вируса на хепатит В, полиовирус или Haemophilus influenzae тип b.
Vaxelis will not prevent disease caused by pathogens other than Corynebacterium diphtheriae, Clostridium tetani, Bordetella pertussis, hepatitis B virus, poliovirus or Haemophilus influenzae type b.
Vaxelis няма да предпази от хепатитна инфекция, която се причинява от други агенти като хепатит А, хепатит С и хепатит Е или от други чернодробни патогени.
Vaxelis will not protect against hepatitis infection caused by other agents such as hepatitis A, hepatitis C and hepatitis E or by other liver pathogens.
Vaxelis се прилага при деца на възраст от шест седмици.
Vaxelis is given to children from the age of six weeks.
Vaxelis ще помогне за предпазване само от тези заболявания, предизвикани от бактериите или вирусите, срещу които е насочена ваксината.
Vaxelis will only help to prevent these diseases caused by the bacteria and viruses targeted by the vaccine.
Vaxxitek HVT+IBD
HVT+IBD
Vaxxitek HVT+IBD
Vaxxitek
Vaxxitek HVT+IBD e рекомбинантна ваксина, предназначена да се използва срещу инфекциозен бурсит (известен още като болест на Гумборо) и Марекова болест по пилетата.
Vaxxitek HVT+IBD is a recombinant vaccine intended for use against Infectious Bursal Disease (also known as Gumboro Disease) and Marek’s Disease in chickens.
Vaxxitek HVT+IBD суспензия и разтворител за инжекционна суспензия
Vaxxitek HVT+IBD Suspension and solvent for suspension for injection
Vaš odmerek zdravila Topotekan Teva bo odvisen od:
Your dose of Topotecan Teva will depend on:
Vaš zdravnik bo uporabil to izračunano površino vašega telesa za določitev pravega odmerka za vas.
Your doctor will use this body surface area to work out the right dose for you.
Vaš zdravnik se bo odločil kako nadaljevati zdravljenje.
Your doctor will decide how to proceed with the treatment.
Vaš zdravnik vam bo morda moral prilagoditi odmerek ali zdravilo ukiniti.
Your doctor may need to adjust or stop your dose.
Vaš zdravnik vam bo povedal, kakšen odmerek morate vzeti, kdaj ga morate vzeti in koliko časa ga morate jemati.
Your doctor will tell you what dose you need to take, when to take it and for how long you need to take it.
Vaš zdravnik, farmacevt ali medicinska sestra vedo, kako pravilno shranjevati zdravilo Zoledronska kislina Actavis.
Your doctor, pharmacist or nurse knows how to store Zoledronic acid Actavis properly.
Vaša telesna masa Odmerek
Your body weight Dose
Vaše cílová hodnota kalorií samotná by Vám měla umožnit snižovat tělesnou hmotnost postupně a stále asi o 0,5 kg za týden, bez toho, že byste měl(a) pocit nespokojenosti nebo strádání.
Your calorie target alone should allow you to lose weight at a gradual, steady pace of about 0.5 kg (1 lb) per week, without feeling frustrated or deprived.
Vaše denní dávka se bude pohybovat v rozmezí 1 až 7 mg v závislosti na Vašem věku a Vaší reakci na přípravek Intuniv, nepřesáhne však 7 mg.
Your daily dose will be between 1 and 7 mg depending on your age and how you respond to Intuniv, but not more that 7 mg.
vaše telesne površine (m2),
your body surface area (m2)
Vaše zdravilo se imenuje Pravafenix.
The name of your medicine is Pravafenix.
Vaši povolenou dávku tuku si rozdělte rovnoměrně do všech jídel během dne.
Distribute your fat allowance evenly across your meals for the day.
Vc (1,3 mg/m2)
Vc (1.3 mg/m2)
Vc = VELCADE; Dx = дексаметазон; T = талидомид a Дозата на талидомид се увеличава до 100 mg от седмица 3 на цикъл 1 само при добра поносимост към дозата от 50 mg и на 200 mg от цикъл 2 до края при добра поносимост към дозата от 100 mg. b Пациентите, постигнали поне частичен отговор след 4 цикъла, може да получат до 6 цикъла на лечение
Vc=VELCADE; Dx=dexamethasone; T=thalidomide a Thalidomide dose is increased to 100 mg from week 3 of Cycle 1 only if 50 mg is tolerated and to 200 mg from cycle 2 onwards if 100 mg is tolerated. b Up to 6 cycles may be given to patients who achieve at least a partial response after 4 cycles
Vc+Dx
Vc+ Dx
Vc+M+P n = 344
Vc+M+P n=344
VCis n = 404
VCis n=404
VCR (1,5 mg/m2/ден, i.v.): дни 1, 8, и 15
VCR (1.5 mg/m2/day, IV): days 1, 8, and 15
VCR (1,5 mg/m2/ден, IV): дни 1, 29
VCR (1.5 mg/m2/day, IV): days 1, 29
VCR (1,5 mg/m2/ден, IV): дни 1, 8 и 15
VCR (1.5 mg/m2/day, IV): days 1, 8, and 15
VCR 1 mg i.v., дни 7, 14;
VCR 1 mg i.v., days 7, 14;
VCR 1 mg i.v., дни 7, 14; IDA 8 mg/m2 i.v.
VCR 1 mg i.v., days 7, 14;
VCR 1,3 g/m2 i.v., ден 1;
VCR 1.3 g/m2 i.v., day 1;
VCR 1,3 g/m² i.v., ден 1;
VCR 1.3 g/m2 i.v., day 1;
VCR 2 mg i.v. месечно за 13 месеца;
VCR 2 mg i.v. monthly for 13 months;
VCR 2 mg i.v. месечно за 13 месеца; Преднизолон 200 mg перорално, 5 дена в месеца за 13 месеца
VCR 2 mg i.v. monthly for 13 months; Prednisolone 200 mg oral, 5 days per month for 13 months
VCR 2 mg обща доза i.v., дни 1, 8, 15, 22;
CR 2 mg total dose i.v., days 1, 8, 15, 22;
VCR 2 mg обща доза i.v., дни 1, 8, 15, 22;
VCR 2 mg total dose i.v., days 1, 8, 15, 22;
VcR-CAP (N = 240)
VcR-CAP
VcR-CAP = VELCADE, ритуксимаб, циклофосфамид, доксорубицин и преднизон; R-CHOP = ритуксимаб, циклофосфамид, доксорубицин, винкристин и преднизон; ПН = периферна невропатия
VcR-CAP=VELCADE, rituximab, cyclophosphamide, doxorubicin, and prednisone; R-CHOP= rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone; PN=peripheral neuropathy
Vd рамо (N = 465)
Vd Arm (N = 465)
VDDx = винкристин, доксорубицин, дексаметазон; VcDx = VELCADE, дексаметазон; TDx = талидомид, дексаметазон; VcTDx = VELCADE, талидомид, дексаметазон; ПН = периферна невропатия
VDDx=vincristine, doxorubicin, dexamethasone; VcDx=VELCADE, dexamethasone; TDx=thalidomide, dexamethasone; VcTDx=VELCADE, thalidomide, dexamethasone; PN=peripheral neuropathy
VDDx=винкристин, доксорубицин, дексаметазон; BzDx=бортезомиб, дексаметазон; TDx= талидомид, дексаметазон; BzTDx=бортезомиб, талидомид, дексаметазон; ПН=периферна невропатия
VDDx=vincristine, doxorubicin, dexamethasone; BzDx= bortezomib, dexamethasone; TDx=thalidomide, dexamethasone; BzTDx= bortezomib, thalidomide, dexamethasone; PN=peripheral neuropathy
VDDx=винкристин, доксорубицин, дексаметазон; BzmbDx=бортезомиб, дексаметазон; TDx= талидомид, дексаметазон; BzmbTDx=бортезомиб, талидомид, дексаметазон; ПН=периферна невропатия
VDDx=vincristine, doxorubicin, dexamethasone; BzmbDx=bortezomib, dexamethasone; TDx=thalidomide, dexamethasone; BzmbTDx=bortezomib, thalidomide, dexamethasone; PN=peripheral neuropathy
Vdihavanje dušikovega oksida lahko vpliva na sposobnost krvi za prenašanje kisika.
Inhaled nitric oxide may influence the oxygen carrying capacity of the blood.
Ve 2 kontrolovaných klinických studiích kombinované terapie s jinými antiretrovirovými léčivými přípravky užívalo 1806 dospělých pacientů atazanavir 400 mg jednou denně (1151 pacientů, medián doby trvání léčby byl 52 týdnů a maxinální doba trvání léčby byla 152 týdnů ) nebo atazanavirem 300 mg posíleným ritonavirem 100 mg jednou denně (655 pacientů, medián doby trvání léčby týdnů a maximální doba trvání léčby 108 týdnů) byly nejčastěji uváděnými nežádoucím účinky nauzea, průjem a žloutenka.
In 2 controlled clinical studies for combination therapy with other antiretroviral medicinal products 1,806 adult patients receiving atazanavir 400 mg once daily (1,151 patients, 52 weeks median duration and 152 weeks maximum duration) or atazanavir 300 mg boosted with ritonavir 100 mg once daily (655 patients, 96 weeks median duration and 108 weeks maximum duration), the most frequently reported adverse reactions were nausea, diarrhoea and jaundice.
Ve skupině, která dostávala atazanavir 300 mg podávaný současně s ritonavirem 100 mg, byly hodnotitelné údaje o genotypu k dispozici pro všech 12 virologických selhání (3%, 12/348) a u žádného pacienta nevznikla rezistence na jakoukoli složku této léčby.
In the group receiving atazanavir 300 mg co-administered with ritonavir 100 mg, evaluable genotypic data was available for all 12 virologic failures (3%, 12/348) and no subject had emergent resistance to any component of the regimen.
ve snížení rozpustnosti
decreased solubility of atazanavir
Ve studii fertility a časných embryonálních vývojových stádií u potkanů změnil atazanavir cyklus říje bez vlivu na páření nebo fertilitu.
In a fertility and early embryonic development study in rats, atazanavir altered oestrus cycling with no effects on mating or fertility.
Ve studii fertility u samic potkanů s dávkami dosahujícími až 22násobku maximální doporučené dávky pro člověka na bázi mg/m2 nebyly pozorovány žádné nežádoucí účinky.
No adverse effects were observed in a fertility study in female rats at doses up to 22 times the maximum recommended human dose on a mg/m2 basis.
Ve studii GS-US-216-0114 bylo 3,6% subjektů pozitivních na povrchový antigen viru hepatitidy B a 5,3% subjektů bylo séropozitivních na virus hepatitidy C. Pacienti s významnými abnormalitami testu jaterních funkcí měli obecně vzato abnormální výchozí hodnotu aminotransferáz (AST nebo
In GS-US-216-0114, 3.6% of subjects were hepatitis B virus surface antigen positive and 5.3% were hepatitis C virus seropositive.
Ve studii GS-US-216-0114 došlo ke snížení odhadované clearance kreatininu v časné fázi léčby kobicistatem s následnou stabilizací.
In study GS-US-216-0114, decreases in estimated creatinine clearance occurred early in treatment with cobicistat, after which they stabilised.
Ve studii GS-US-216-0114 se po dobu 144 týdnů léčby často objevila hyperbilirubinemie (> 1x ULN (horní hranice normálních hodnot)): u 97,7% jedinců ve skupině s atanazavirem posíleným kobicistatem podávaným současně s kombinací fixní dávky emtricitabinu a tenofovir-disoproxyl-fumarátu a u 97,4% jedinců ve skupině s atanazavirem posíleným ritonavirem podávaném současně s kombinací fixní dávky emtricitabinu a tenofovir-disoproxyl-fumarátu.
In study GS-US-216-0114, through 144 weeks of treatment hyperbilirubinaemia (> 1 x ULN) was common: 97.7% in the atazanavir boosted with cobicistat plus emtricitabine and tenofovir disoproxil fumarate fixed-dose combination group, and 97.4% in the atazanavir boosted with ritonavir plus emtricitabine and tenofovir disoproxil fumarate fixed-dose combination group.
Ve studii lékových interakcí indukovalo podání přípravku Intuniv v kombinaci s lisdexamfetamin- mesilátem 19% nárůst maximální plazmatické koncentrace guanfacinu, zatímco expozice (AUC) se zvýšila o 7 %.
In a drug interaction study, administration of Intuniv in combination with lisdexamfetamine dimesylate induced a 19% increase in guanfacine maximum plasma concentrations, whereas exposure (AUC) was increased by 7%.
Ve studii lékových interakcí neprokázal přípravek Intuniv ani OROS (Osmotic Release Oral System) methylfenidát HCl s prodlouženým uvolňováním vliv na farmakokinetiku jiných léčivých přípravků při podání v kombinaci.
In a drug interaction study, neither Intuniv nor Osmotic Release Oral System (OROS)- methylphenidate HCl extended-release were found to affect the pharmacokinetics of the other medicinal products when taken in combination.
Ve studii opakovaného podávání
Cobicistat
Ve studii prováděné u jedinců s normální hmotností a jedinců obézních nevedly jednotlivé dávky 800 mg orlistatu a opakované dávky do 400 mg podávané třikrát denně po dobu 15 dní k signifikantním klinickým nálezům.
Single doses of 800 mg orlistat and multiple doses of up to 400 mg three times daily for 15 days have been studied in normal weight and obese subjects without significant clinical findings.
Ve studii přídatné terapie u parciálních respondérů na psychostimulanciích byl sledován účinek současného podání guanfacinu s psychostimulancii.
The effect of co-administration with psychostimulants was examined in an add-on study in partial responders to psychostimulants.
Ve studii toxicity po perorálním podání atazanaviru a kobicistatu u potkanů, která trvala 3 měsíce, nebyly pozorovány žádné zjevné toxikologické interakce ani aditivní nebo synergická toxicita.
In a 3-month combination oral toxicity study of atazanavir and cobicistat in rats, there were no toxicologic interactions apparent as no additive or synergistic toxicities were observed.
Ve studiích in vitro, při koncentraci atazanaviru (30 μm) odpovídající 30násobku Cmax koncentrace nevázaného léčiva u lidí, byly draslíkové kanály klonovaných lidských kardiocytů (hERG) inhibovány z 15%.
During in vitro studies, cloned human cardiac potassium channel (hERG), was inhibited by 15% at a concentration (30 μM) of atazanavir corresponding to 30 fold the free drug concentration at Cmax in humans.
Ve studiích vývojové toxicity u potkanů a králíků nebyly pozorovány žádné teratogenní účinky.
No teratogenic effects were observed in rats and rabbit developmental toxicity studies.
Ve vztahu k etnickému původu nebyly u atazanaviru ani kobicistatu zaznamenány žádné klinicky významné rozdíly.
No clinically relevant pharmacokinetic differences due to ethnicity have been identified for atazanavir or cobicistat.
Ve vztahu k pohlaví nebyly u atazanaviru ani kobicistatu zaznamenány žádné klinicky významné rozdíly.
No clinically relevant pharmacokinetic differences due to gender have been identified for atazanavir or cobicistat.
Ve většině případů byla žloutenka hlášena během několika málo dnů až měsíců od zahájení léčby (viz bod 4.4).
In the majority of cases, jaundice was reported within a few days to a few months after the initiation of treatment (see section 4.4).
VE Ефективност на ваксината (FinIP) или ефикасност на ваксината (COMPAS) N Брой участници в група
VE Vaccine effectiveness (FinIP) or efficacy (COMPAS) N number of subjects per group
Vectibix 20 mg/ml концентрат за инфузионен разтвор Панитумумаб
Vectibix 20 mg/mL concentrate for solution for infusion Panitumumab
Vectibix 20 mg/ml концентрат за инфузионен разтвор панитумумаб (panitumumab)
Vectibix 20 mg/mL concentrate for solution for infusion panitumumab
Vectibix в комбинация със схемата FOLFIRI е изследван в основно проучване при 1186 лекувани преди това пациенти, като Vectibix е сравнен с химиотерапия, приложена самостоятелно.
Vectibix in combination with FOLFIRI has been investigated in a main study involving 1,186 patients who had been treated before, where Vectibix was compared with chemotherapy alone.
Vectibix в комбинация със схемата FOLFIRI е изследван в проучване при 154 нелекувани преди това пациенти, като проучването разглежда основно броя на пациентите, които се повлияват от лечението.
Vectibix in combination with FOLFIRI has been investigated in a study involving 154 previously untreated patients which looked mainly at the percentage of patients who responded to treatment.
Vectibix в комбинация със схемата FOLFOX е изследван в основно проучване при 1183 пациенти, които не са лекувани преди това за метастатичен рак, като Vectibix е сравнен с химиотерапия, приложена самостоятелно.
Vectibix in combination with FOLFOX has been investigated in a main study involving 1,183 patients who had not been treated before for their metastatic cancer, where Vectibix was compared with chemotherapy alone.
Vectibix е безцветна течност, която може да съдържа видими частици и се предлага във флакони.
Vectibix is a colourless liquid that may contain visible particles and is supplied in a vial.